Riskpilot← Back to searchSign inGet full accessEvolab AB
ABActiveOrg 5567585285Kåkbrinken 14Industrial product and fashion design activities · NACE 7411Est. 20081 employees
Revenue 2025
SEK 3,4M
+297% vs 2024
EBITDA margin
32.6%
+350% vs 2024
Equity ratio
43.2%
Financial strength
Net profit 2025
SEK 669K
+173% vs 2024
| Revenue | SEK 3,4M | +297% |
| EBITDA | SEK 1,1M | +350% |
| Net profit | SEK 669K | +173% |
| Total assets | SEK 2,4M | +205% |
| Equity | SEK 1M | +120% |
| Employees | 1 | — |
Legal name
Evolab AB
Org number
5567585285
Legal form
Aktiebolag
NACE code
7411 · Industrial product and fashion design activities
Founded
26 maj 2008
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva konsultverksamhet inom strategisk design management och design, samt design, produktion, marknadsföring och försäljning av konfektion och accessoarer, samt därmed förenlig verksamhet.
Address
Kåkbrinken 14
Email
anna@evolab.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 033 | 322 | 44 | 847 | 3 362 |
| Staff expenses | — | −495 | −286 | −387 | −850 |
| EBITDA | −106 | −360 | −296 | 244 | 1 096 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −106 | −360 | −296 | 244 | 1 096 |
| Net financials | — | — | 1 | 1 | 1 |
| Profit before tax | 14 | −145 | −295 | 245 | 833 |
| Tax | −11 | — | — | — | −164 |
| Net profit | 3 | −145 | −295 | 245 | 669 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 550 | 799 | 277 | 794 | 2 422 |
| Equity | 991 | 627 | 231 | 476 | 1 045 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 344 | 172 | 46 | 318 | 1 112 |
| Total debt | 344 | 172 | 46 | 318 | 1 112 |
EBITDA margin
32.6%
This company
15.8%
Market median
+106% vs market
20212025
Equity ratio
43.2%
This company
38.2%
Market median
+13% vs market
20212025
Return on equity
64.0%
This company
18.4%
Market median
+248% vs market
20212025
Net profit margin
19.9%
This company
8.1%
Market median
+146% vs market
20212025
Asset turnover
1.39×
This company
1.12×
Market median
+24% vs market
20212025
Debt / equity
1.32×
This company
0.62×
Market median
-113% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AA Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Evolab AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna A V Kamjou-Reuterswärd | Chief Executive Officer | 0 companies |
| Jonas Anton Kamjou-Reuterswärd | Deputy Board Member | 0 companies |